351 results about "Sphingosine" patented technology

Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon chain (e.g., a lysolipid such as lysophosphatidic acid or sphingosine-1-phosphate) in which a carbon atom has been derivatized with a pendant reactive group; immunogens made by linking a derivatized lipid to a carrier moiety (e.g., a carrier protein, polyethylene glycol, colloidal gold, alginate, or a silicone bead); monoclonal antibodies and derivatives produced by immunizing an animal with such an immunogen; and therapeutic and diagnostic compositions containing such antibodies and antibody derivatives. Methods for making such derivatized lipids, immunogens, and monoclonal antibodies and derivatives, methods for detecting such antibodies once generated, and therapeutic and diagnostic methods for using such antibodies and derivatives, are also described.

The invention relates to Sphingomonas sp. TP-5 and a method and an application of the same for producing welan gum. A strain of the invention is prepared by separating and acclimating sugar-contained wastewater in a molasses plant, has a systematic name of Sphingomonas sp. and a preservation number of CGMCCNo.3097, not only can grow in nutrient media of beef broth, LB and nutrient agar, but also can grow in a sugar-contained inorganic-salt culture medium. The TP-5 strain can be fermented in the sterile culture medium containing sugar, inorganic salt and water at a temperature condition of 28-37 DEG C; ymotic fluid is extracted to obtain the welan gum achieving a temperature-resistant limit value of 150 DEG C; and potassium chloride in different concentrations is added so that a welan gum solution remarkably improves the viscosity, enhances the temperature stability, does not vary the viscosity with temperature and presents stronger temperature tolerance, thereby being applied to seawater drilling mud and a high salinity reservoir viscous water flooding system.

The present invention relates to DNA segments isolated from Sphingomonas sp. and involved in the biosynthetic production of sphingan polysaccharides to increase the production of the polysaccharide in engineered microorganisms. The present invention also relates to methods of engineering strains of Sphingomonas to produce bacteria which are hyperproducers of sphingan, methods of identifying and utilizing DNA fragments useful to enhance production of sphingan in bacteria and the hyperproducer bacteria.

The invention relates to mutant strains of the genus Sphingomonas which have a mutation in at least one gene encoding a protein involved in polyhydroxybutyrate (“PHB”) synthesis that allows the mutant strains to produce PHB-deficient sphingans. The invention is also directed to a process for preparing a clarified sphingan solution comprising heating aqueous sphingan solution, in particular PHB-deficient sphingan solution, to a clarification temperature of about 30° C. to about 70° C., and treating the solution with a clarification agent and enzymes. In addition, the invention is directed to a food or industrial product comprising a PHB-deficient and / or clarified sphingan. One particular embodiment of the invention is directed to a clarified, PHB-deficient high-acyl gellan and the processes of making thereof.

Described are methods for protecting the female reproductive system against natural and artificial insults by administering to women a composition comprising an agent that antagonizes one or more acid sphingomyelinase (ASMase) gene products. Specifically, methods disclosed herein serve to protect women's germline from damage resulting from cancer therapy regimens including chemotherapy or radiotherapy. In one aspect, the method preserves, enhances, or revives ovarian function in women, by administering to women a composition containing sphingosine-1-phosphate, or an analog thereof. Also disclosed are methods to prevent or ameliorate menopausal syndromes and to improve in vitro fertilization techniques.

In vitro / cell-free process of preparing a sialylated oligosaccharides are described. The sialylated oligosaccharides include gangliosides. The oligosaccharides linked to various moieties including sphingoids and ceramides. Novel compounds that comprise sphingoid groups are disclosed. The compounds include sialylated oligosaccharides including gangliosides as well as various sphingoids and ceramides.

Provided is a ceramide emulsion containing the following components (A), (B) and (C) and not containing an acrylic acid polymer or a phospholipid: (A) sphingosines represented by Formula (1): (wherein R1 represents a hydrocarbon group having 4 to 30 carbon atoms which is optionally substituted with a hydroxyl group and the like; Y represents CH2, CH or O; X1, X2 and X3 represent H, a hydroxyl group or an acetoxy group; X4 represents H, an acetyl group or a glyceryl group or, together with an adjacent O atom, forms an oxo group; R2 and R3 represent H, a hydroxyl group, a hydroxymethyl group or an acetoxymethyl group; groups “R”s are H or an amidino group or represent a hydrocarbon group having 1 to 8 carbon atoms which may have a substituent such as a hydroxyl group and the like; and “a” is 2 or 3), (B) an acidic compound selected from inorganic acids and organic acids having a molecular weight of 200 or less, and (C) ceramides represented by Formula (2): (wherein R7 represents a hydrocarbon group having 4 to 30 carbon atoms which is optionally substituted with a hydroxyl group and the like; Z represents CH2, CH or O; X5, X6 and X7 represent H, a hydroxyl group or an acetoxy group, X4 represents H, an acetyl group or a glyceryl group or, together with an adjacent O atom, forms an oxo group; R8 and R9 represent H, a hydroxyl group, a hydroxymethyl group or an acetoxymethyl group; R10 represents a hydrocarbon group having 5 to 60 carbon atoms which is optionally substituted with a hydroxyl group and the like; and R11 represents H or a hydrocarbon group having 1 to 8 carbon atoms which optionally have a substituent such as a hydroxyl group and the like).

The invention relates to a method for preparing phytosphingosine liposome composition having excellent long-term storage stability and the method comprises dispersing phytosphingosine in water, separately dissolving phospholipid in a solvent and mixing the two solutions prepared by the above procedures.

The invention relates to a microbial strain which can produce sphingosine, dihydrosphingosine, phytosphingosine and / or the derivatives thereof with improved level. In addition, the invention further discloses a method which is based on induced mutation or other selection technologies, and the strain is prepared accordingly. As an example, a mutant strain of pichia pastris is provided; and compared with the wild-type strain, compounds produced by the mutant strain are higher by about 50 percent.

Novel glycolipid derivatives, where the substituent of the sphingosine base part is a short carbon chain alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted aryl group or substituted or unsubstituted aralkyl group and efficient synthetic methods for practical mass production of the same and intermediates useful for the synthesis of these compounds. Glycolipids having the formula (I): where R3 indicates a substituted or unsubstituted C1 to C7 linear alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted aryl group, or substituted or unsubstituted aralkyl group and R8 indicates a substituted or unsubstituted C1 to C35 alkyl group, substituted or unsubstituted aryl group or substituted or unsubstituted aralkyl group are chemically synthesized.

Disclosed is a prediction method of glomerular filtration rate (GFR) from urine samples after kidney transplantation to provide an information needed for predict renal function after the transplantation, more particularly to a prediction method of glomerular filtration rate (GFR) from urine samples after kidney transplantation, which comprises detecting metabolic profiles of five biomarkers, 5a-androst-3-en-17-one (AS), glycocholic acid (GC), sphingosine (SG), tryptophan (TR) and histidine (HT), from urine samples of patients. Glomerular filtration rate (GFR) after kidney transplantation can be predicted more rapidly and precisely to provide an information needed for predict renal function after the transplantation by using five metabolites as biomarkers. The method provides more specific, sensitive, and reliable biomarkers that monitor clinical outcomes and adverse renal events after kidney transplantation, such as rejection, drug toxicity, delayed graft function, and infection.

The invention discloses an acne removing essence with added pearl hydrolyzate liposomes, which is prepared by mixing and stirring glycerol, 1,3-butanediol, ethylenediaminetetraacetic acid disodium salt, pearl hydrolyzate liposomes, plant sphingosine, dipotassium glycyrrhizate, imidazolidinyl urea and deionized water; the preparation process is that the glycerol, the 1,3-butanediol, the ethylenediaminetetraacetic acid disodium salt and the deionized water are mixed and evenly stirred, the pearl hydrolyzate liposomes, the plant sphingosine, the dipotassium glycyrrhizate and the imidazolidinyl urea are added for stirring after the heating, heat preservation and cooling, and the discharge obtains the finished product. The pearl hydrolyzate liposomes containing a variety of amino acids are added in the acne removing essence, which is not only anti-inflammatory, bactericidal and can remove acnes, but also can effective enhance the metabolic function of skin cells, dredge the pores of the skin cells and promote the regeneration of the surface cells, so the acne removing essence can effectively repair the damaged skin, accelerate the healing of damaged skin open sores and acne spots and ensuring the skin to be delicate, smooth, white and moist.

A method of treating a subject in need of a cell or tissue transplant is disclosed. The method comprising (a) transplanting a non-syngeneic cell or tissue transplant into the subject, wherein the transplant comprises bone marrow or lymphoid cells; and (b) administering to the subject a therapeutically effective amount of an immunosuppressive regimen comprising a Sphingosine 1-Phosphate Receptor Agonist, a B7 molecule inhibitor and a CD2 / CD58 pathway inhibitor, thereby treating the subject.

An oil-in-water emulsified composition containing; (A) ester oil which is in liquid state at 25° C. (B) sphingosines represented by the formula (1) (wherein, R1 represents hydrocarbon group which may have a substituent; Y represents a methylene group, a methine group or an oxygen atom; X1,X2 and X3 are H, OH or an acetoxy group; X4 represents H, an acetyl group or the like; R2 and R3 are H, OH and the like; R represents H or an amidino group; “a” stands for 2 or 3;) (C) an acid compound selected from the group consisting of inorganic acid or an organic acid having 5 or less carbon atoms, and (D) cholesterol or phytosterol, wherein the ratio of a liquid oil component containing Component (A) in the total amount of oil phase is 5 to 90 wt %.

The invention relates to a Sphingomonas sp. T-3 and a method for producing biological polysaccharide and poly-beta-hydroxy-butanoic acid by co-fermentation. The collection number of the Sphingomonas sp. strain T-3 is CGMCC No.10150. The method comprises the following steps: carrying out activating culture on the strain T-3, inoculating into a seed culture medium, inoculating a seed solution into the fermentation culture medium, and culturing; and after the fermentation finishes, diluting with distilled water, heating, carrying out membrane separation to obtain a supernate and a thallus precipitate; regulating the pH value of the supernate to 3.0 or so with hydrochloric acid, regulating the pH value of the obtained precipitate to neutrality with NaOH, and drying to obtain the biological polysaccharide; and drying the thallus precipitate, extracting with chloroform, and drying the supernate to obtain the poly-beta-hydroxy-butanoic acid. In the strain T-3 fermentation process, abundant poly-beta-hydroxy-butanoic acid is accumulated in the cells, and abundant biological polysaccharide is secreted into the culture medium; and the two obtained products can be widely used in the fields of industry, food, medical treatment and the like.

The invention relates to a synergistic effect of multiple bacterial strains on degradation of polyphenol pollutants and a research method thereof. According to the invention, a bacterial suspension is prepared from one or a mixture of two or three selected from the group consisting of pseudomonas aeruginosa GIMT1.074, sphingobacterium multivorum CICC 23249 and ochrobactrum sp. BJS2; then the bacterial suspension is inoculated to inorganic a salt medium containing phenol, meta-cresol and 4-chlorophenol with different concentrations for culture; parts of a culture solution are taken out at different time intervals to measure concentrations of phenol, meta-cresol and 4-chlorophenol in the culture solution so as to determine degradation rates at different times, and cell concentrations in the culture solution are measured to investigate growth conditions of different cells. According to research on synergistic degradation effects of the three phenol degrading bacteria, a mixed bacterial strain has superior capability in degradation of mixed phenolic pollutants and has much better degradation efficiency and effects compared to every individual bacterial strain; moreover, biomass of the mixed bacterial strain is increased to two times of the biomass of an original optimal bacterial strain, i.e., the pseudomonas aeruginosa GIMT1.074.

Prodrugs comprising a lipophilic drug linked to a transport moiety that can be taken up by a fatty acid transporter are provided. The transport moiety comprises a lipid chain connected to a hydrophilic group (e.g. a carboxylic acid, a phosphate, or a sphingosine-like moiety). Due to the presence of the transport moiety, the prodrugs are substrates for endogenous fatty acid transporter systems. The transport moiety thus serves as a carrier or targeting moiety to facilitate uptake of the entire prodrug complex by endogenous fatty acid transporter systems, thereby moving the prodrug into cells and tissues where drug distribution and effects are desired. Hydrolysis of the chemical linkage between the lipid-like moiety and the lipophilic drug releases the drug in an active form within the cells or tissues.

Materials and Method for treating cancer and screening for anti-neoplastic agents are provided. These materials and methods can include sphingosine 1-phosphate antagonists that bind to sphingosine-1 phosphate receptor subtype 3. Antibodies and aptamers that selectively bind to an epitope in the extracellular loop between transmembrane domains two and three of sphingosine-1-phosphate receptor subtype 3 are provided.

The present invention provides methods for producing human ceramide in a yeast cell.The methods of the present invention comprise:1) introducing the sphingoid Δ4-desaturase gene (DES1) by transformation of the yeast cell; and2) abolishing the expression of the yeast sphinganine C4-hydroxylase gene (SUR2) by transformation of the yeast cell.

There are disclosed compound of formula I, in which R1 represents a hydrophobic moiety adapted to occupy the C′ channel of human CDId, R2 represents a hydrophobic moiety adapted to occupy the A′ channel of human CDId, such that R1 fills at least at least 30% of the occupied volume of the C′ channel compared to the volume occupied by the terminal nC14H29 of the sphingosine chain of α-galactosylceramide when bound to human CDId and R2 fills at least 30% of the occupied volume of the A′ channel compared to the volume occupied by the terminal nC25H51 of the acyl chain of α-galactosylceramide when bound to human CDId R3 represents hydrogen or OH, Ra and Rb each represent hydrogen and in addition, when R3 represents hydrogen, Ra and Rb together may form a single bond, X represents or —CHA(CHOH)nY or —P(═0)(0−)0CH2(CH0H)mY, in which Y represents CHB1B2, n represents an integer from 1 to 4, m represents 0 or 1, A årepresents hydrogen, one of B1 and B2 represents H, OH or phenyl, and the other represents hydrogen or one of B1 and B2 represents hydroxyl and the other represents phenyl, in addition, when n represents 4, then A together with one of B1 and B2 together forms a single bond and the other of B1 and B2 represents H, OH or OSO3H and pharmaceutically acceptable salts thereof; the compounds of formula I are indicted for use in the treatment of a virus, microbial infection, parasite, an autoimmune disease, cancer, allergy or asthma

The invention discloses Sphingobacterium sp. with an aniline degradation capability. The 16 SrDNA of the Sphingobacterium sp. is identified as Sphingobacterium sp., and is numbered BA-4; the Sphingobacterium sp. is collected in the China General Microbiological Culture Collection Center with the collection number CGMCC No.:13428; the Sphingobacterium sp. is a short rod, and belongs to a Gram-negative bacterium; a round faint yellow bacterial colony is formed on a beef extract-peptone solid culture medium, and is wet in surface, neat in edge and easy to pick. The invention further discloses an application of the Sphingobacterium sp. to aniline degradation. The Sphingobacterium sp. BA-4 is applied to degradation of aniline in a sewage system, has very high degradation rate and tolerance concentration, is free from secondary pollution, is safe to use, and has a wide application prospect.

The invention belongs to the technical field of daily care products and discloses a moisturizing and repairing composition and an epidermis biomimetic membrane liquid crystal complex constructed therefrom. The core components of the moisturizing and repairing composition and the epidermis biomimetic membrane liquid crystal complex include ceramide, phytosphingosine, cholesterol, lauryl glutamate, squalane, myristyl alcohol, cetostearyl alcohol, arginine, glycine and hydroxyproline. In the invention, by means of combination of various raw materials and through a layered liquid crystal forming mechanism, the special epidermis biomimetic membrane is developed, by which a lamellar liquid crystal body, which likes a keratinocyte intercellular lipid layer, can be formed, so that an effect of protecting skin and improving skin can be achieved.

To provide a fat accumulation inhibitor and a food or drink for inhibiting fat accumulation, a visceral fat accumulation inhibitor and a food or drink for inhibiting visceral fat accumulation, or an agent for accelerating increase and / or inhibiting decrease of an adiponectin concentration in blood and a food or drink for accelerating increase and / or inhibiting decrease of an adiponectin concentration in blood.A fat accumulation inhibitor for a fat cell, which comprises a milk-derived phospholipid as an active ingredient, and a food or drink for inhibiting fat accumulation in a fat cell, which comprises a milk-derived phospholipid. A visceral fat accumulation inhibitor comprising a sphingosine-containing phospholipid or a derivative thereof as an active ingredient, and a food or drink for inhibiting visceral fat accumulation. An agent for accelerating increase and / or inhibiting decrease of an adiponectin concentration in blood, which comprises a sphingosine-containing phospholipid or a derivative thereof as an active ingredient, and a food or drink for accelerating increase and / or inhibiting decrease of an adiponectin concentration in blood.

The invention provides sphingobium yanoikuyae with a function of degrading triphenyl phosphate. The bacterium is named YC-XJ2, has a preservation number of CGMCC No.18049, and enables 100mg / L TPhP ininorganic salt to be degraded by 99.7 percent in 24 hours. The sphingobium yanoikuyae strain YC-XJ2 has strong adaptability on temperature, can keep the degradation rate on TPhP at 95 percent at 40 DEG C, can keep the degradation rate on TPhP at 88 percent or more when the pH value is 4-10, has a degradation at 74.8 percent or more when the salt concentration is 0-10 percent, and shows extremely strong salt resistance. The strain can be applied to biological repairing of a TPhP polluted environment and has relatively good economic value and application prospect.